Emerging targeted therapies in triple-negative breast cancer.
暂无分享,去创建一个
[1] I. Roninson,et al. Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(−) triple-negative breast cancer (TNBC) cell line , 2011 .
[2] Anthony Rhodes,et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[4] V. Valero,et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[6] A. Ashworth,et al. BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.
[7] E. Díaz-Rubio,et al. Phase II study of carboplatin in advanced breast cancer: preliminary results. , 1991, Seminars in oncology.
[8] H. Rugo,et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Z. Mechl,et al. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. , 1984, Neoplasma.
[10] A. Melnick,et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.
[11] R. Greil,et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. T. Thigpen. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011 .
[13] J. Hoeijmakers. Genome maintenance mechanisms for preventing cancer , 2001, Nature.
[14] K. Kolarić,et al. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer , 2004, Cancer Chemotherapy and Pharmacology.
[15] K. A. Gelmon. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[16] E. Winer,et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. , 2010 .
[17] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[18] K. Kolarić,et al. Carboplatin activity in untreated metastatic breast cancer patients — results of a phase II study , 2004, Cancer Chemotherapy and Pharmacology.
[19] Z. Hall. Cancer , 1906, The Hospital.
[20] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[21] B. Schneider,et al. Angiogenesis of breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Kern,et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Jorge S Reis-Filho,et al. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.
[24] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[25] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[26] N Harbeck,et al. Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] D. Talbot,et al. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Larkin,et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours , 2011, British Journal of Cancer.
[29] J. Baselga,et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Amadori,et al. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Eric Sauerbrei,et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Katherine S Panageas,et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[34] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Daniel Birnbaum,et al. How basal are triple‐negative breast cancers? , 2008, International journal of cancer.
[36] W. Wood,et al. Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study. , 1985, Cancer treatment reports.
[37] J. Hainsworth,et al. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. , 2011, Clinical advances in hematology & oncology : H&O.
[38] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[39] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[40] E. Chu,et al. Highlights From: The 4th International Congress on Colorectal Cancer; Aventura, Florida, October 2005 , 2005 .
[41] M. Clynes,et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] I. Roninson,et al. Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer , 2009 .
[43] E. Perez,et al. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.
[44] J. O’Shaughnessy,et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer , 2007 .
[45] E. McDermott,et al. Src: a potential target for the treatment of triple-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] J. Baselga,et al. SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). , 2009 .
[47] S. Loibl,et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer , 2009, Anti-cancer drugs.
[48] N. Bachur,et al. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. , 1980, Cancer clinical trials.
[49] G. Viale,et al. Management of triple negative breast cancer. , 2010, Breast.
[50] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] V. Schreiber,et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. , 2000, Biochemistry.
[52] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[53] I. Ellis,et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.
[54] R. Wittes,et al. Cisplatin in the treatment of metastatic breast carcinoma A prospective randomized trial of two dosage schedules , 1982, American journal of clinical oncology.
[55] H. Nevanlinna,et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer , 2008, Oncogene.
[56] L. Neckers,et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[57] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[58] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] C. Perou,et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .
[60] D. Bajorin,et al. Phase I trial of escalating doses of cisplatin in hypertonic saline. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] N. Ibrahim,et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. , 2009 .
[62] G. Hortobagyi,et al. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. , 1978, Cancer treatment reports.
[63] G. Sledge,et al. Cisplatin as first-line therapy for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] C. Caldas,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[66] E. Friedman,et al. Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.
[67] E. Alli,et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.
[68] S. Swain,et al. Ixabepilone: clinical role in metastatic breast cancer. , 2011, Clinical breast cancer.
[69] M. Rezai,et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Mark T. W. Ebbert,et al. Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials. , 2009 .
[71] C. Hudis,et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.